DNTH - Company ID 0001690585
The table below shows Dianthus Therapeutics, Inc. /DE/'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $627.67M | $55.98M | $13.24M | $10.12M | $33.67M | $314.17M |
| Short-term investments | $483.59M | $346.63M | $244.15M | $253.11M | $247.45M | $46.54M |
| Receivables | $1.23M | $5.00M | $39.00K | $1.00M | $1.39M | $840.00K |
| Inventory | - | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $1.12B |
| $413.82M |
| $263.61M |
| $271.00M |
| $287.49M |
| $365.69M |
| Property, plant & equipment | $274.00K | $185.00K | $207.00K | $191.00K | $189.00K | $189.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $1.25B | $577.45M | $326.08M | $348.58M | $354.25M | $368.96M |
| Accounts payable | $5.27M | $6.71M | $5.40M | $8.27M | $7.57M | $3.69M |
| Total current liabilities | $38.28M | $23.86M | $20.09M | $16.95M | $15.71M | $10.03M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $45.57M | $30.99M | $23.00M | $19.97M | $16.35M | $10.74M |
| Retained earnings | -$377.56M | -$272.30M | -$235.53M | -$203.90M | -$145.95M | -$120.78M |
| Total equity | $1.20B | $546.45M | $303.08M | $328.61M | $337.90M | $358.22M |